Perjeta® gets regulatory green light for use in early HER2-positive breast cancer prior to surgery

Perjeta (pertuzumab) regimen nearly doubled number of women whose tumours are eradicated versus standard treatment

Source: Pharmacy Europe - September 28, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Personalised medicine Practical therapeutics Oncology Research breast cancer her2 HER2-positive breast cancer herceptin Latest News NEOSPHERE perjeta TRYPHAENA Source Type: news